Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

381. Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease

Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Article Text Therapeutics Picotamide

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

382. Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk

Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Article Text Therapeutics Review: antiplatelet agents (particularly

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

383. Sex differences in platelet reactivity and response to low-dose aspirin therapy. (PubMed)

Sex differences in platelet reactivity and response to low-dose aspirin therapy. Recent randomized trials suggest that women may not accrue the same cardioprotective benefits as men do from low-dose aspirin therapy used in primary prevention. Failure of aspirin to suppress platelet aggregation in women is one hypothesized mechanism.To examine differential platelet reactivity to low-dose aspirin therapy by sex.A clinical trial of aspirin at 81 mg/d for 14 days was conducted in 571 men and 711 (...) women. Baseline and post-aspirin therapy measures included platelet aggregation to arachidonic acid, adenosine diphosphate, epinephrine, and platelet function analyzer closure time.Sex differences in cyclooxygenase 1 (COX-1) direct and indirect platelet activation pathways before and after administration of aspirin.In 10 of the 12 platelet agonist exposures, women's platelets were significantly more reactive at baseline. However, after aspirin therapy, the percent aggregation to arachidonic acid

Full Text available with Trip Pro

2006 JAMA

384. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. (PubMed)

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied.To perform a cost-utility analysis of the effects of aspirin therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the primary prevention of CHD events in men.Markov model.Published (...) literature.Middle-aged men without a history of cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 15%, and 25%).Lifetime.Third-party payer.Low-dose aspirin, a statin, both drugs as combination therapy, or no therapy.Cost per quality-adjusted life-year gained.For 45-year-old men who do not smoke, are not hypertensive, and have a 10-year risk for CHD of 7.5%, aspirin was more effective and less costly than no treatment. The addition of a statin to aspirin therapy produced

2006 Annals of Internal Medicine

385. Aspirin resistance. (PubMed)

Aspirin resistance. Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A2 and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance may correlate independently with increasing risk of cardiovascular events. Aspirin resistance can be detected by laboratory tests of platelet thromboxane A2 production or platelet function that depend on platelet thromboxane production. Potential causes of aspirin resistance include inadequate (...) dose, drug interactions, genetic polymorphisms of COX-1 and other genes involved in thromboxane biosynthesis, upregulation of non-platelet sources of thromboxane biosynthesis, and increased platelet turnover. Aspirin resistance can be overcome by treating the cause or causes, and reduced by minimising thromboxane production and activity, and blocking other pathways of platelet activation. Future research is aimed at defining aspirin resistance, developing reliable tests for it, and establishing

2006 Lancet

386. Clopidogrel plus aspirin or aspirin alone in unstable angina

Clopidogrel plus aspirin or aspirin alone in unstable angina BestBets: Clopidogrel plus aspirin or aspirin alone in unstable angina Clopidogrel plus aspirin or aspirin alone in unstable angina Report By: Shweta Gidwani - Clinical Effectiveness Fellow Search checked by Richard Body - Clinical Research Fellow Institution: Manchester Royal Infirmary Original author: Shweta Gidwani Original institution: Manchester Royal Infirmary Date Submitted: 25th November 2005 Date Completed: 2nd February 2006 (...) with oxygen, aspirin, nitrates, beta-blockers and heparin, after which he becomes pain free. You also give him clopidogrel 300 mg because you have heard that patients with unstable angina and non ST-elevation MI have a better cardiovascular outcome when treated with a combination of clopidogrel and aspirin versus aspirin alone. You wonder whether there is any evidence to support this. Search Strategy Medline 1966–11/2005 using the OVID interface Embase 1980–2005 week 47 The Cochrane Library Issue 4 2005

2006 BestBETS

387. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. (PubMed)

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. Aspirin therapy reduces the risk of cardiovascular disease in adults who are at increased risk. However, it is unclear if women derive the same benefit as men.To determine if the benefits and risks of aspirin treatment in the primary prevention of cardiovascular disease vary by sex.MEDLINE and the Cochrane Central Register of Controlled Trials databases (...) (1966 to March 2005), bibliographies of retrieved trials, and reports presented at major scientific meetings. Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality. Six trials with a total of 95 456 individuals were identified; 3 trials included only men, 1 included only women, and 2 included both sexes.Studies were reviewed to determine

2006 JAMA

388. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis

Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Larsson S C, Giovannucci E, Bergkvist L, Wolk A CRD summary The authors concluded that current evidence does not support a link between aspirin and non-steroidal anti-inflammatory drug use and risk (...) of pancreatic cancer. The limited search, absence of a formal validity assessment and limited details about the included studies make it difficult to assess the reliability of the authors’ conclusions. Authors' objectives To investigate the relationship between use of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, and risk of pancreatic cancer. Searching MEDLINE was searched from 1966 to October 2006 for articles in any language; the search terms were reported. The reference lists

2006 DARE.

389. Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Article Text Therapeutics Clopidogrel plus aspirin

2006 Evidence-Based Medicine (Requires free registration)

390. Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia

Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischaemia Article Text

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

391. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Article Text

2006 Evidence-Based Medicine (Requires free registration)

392. Aspirin

Aspirin Aspirin ASP Drugs October 2006 Page 1 of 1 Drugs PRESENTATION 300 milligram aspirin (acetylsalicylic acid) in tablet form (dispersible). ACTIONS Has an anti-platelet action which reduces clot formation. Analgesic, anti-pyretic and anti-in?ammatory. CAUTIONS As the likely bene?ts of a single 300 milligram aspirin outweigh the potential risks, aspirin may be given to patients with: Asthma Pregnancy Kidney or liver failure Gastric or duodenal ulcer SIDE EFFECTS Gastric bleeding. Wheezing (...) in some asthmatics. DOSAGE AND ADMINISTRATION Adults Adults with apparent, suspected or possible myocardial infarction. Route: Oral – chewed or dissolved in water INDICATIONS Adults with: clinical or ECG evidence of myocardial infarction or ischaemia central chest pain, possibly of cardiac origin. Aspirin should be administered to any patient with chest pain unless the diagnosis is very clearly non- cardiac or the drug is contraindicated. CONTRA-INDICATIONS Known aspirin allergy or sensitivity

2006 Joint Royal Colleges Ambulance Liaison Committee

393. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Pignone M, Earnshaw S, Tice J A, Pletcher M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of aspirin, statins, and a combination of aspirin and statins for the primary prevention of coronary heart disease (CHD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

2006 NHS Economic Evaluation Database.

394. Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation

Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Annemans L, Lamotte M, Kubin M, Evers T, Verheugt F W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of low-dose aspirin (75 to 325 mg) in the primary prevention of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients aged

2006 NHS Economic Evaluation Database.

395. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

396. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

397. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. (PubMed)

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed (...) them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes.The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence interval, 0.83 to 1.05; P=0.22). The respective rate of the principal secondary efficacy end point, which included hospitalizations for ischemic events, was 16.7 percent and 17.9

Full Text available with Trip Pro

2006 NEJM Controlled trial quality: predicted high

398. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. (PubMed)

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral (...) anticoagulation therapy for prevention of vascular events.Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated to receive oral anticoagulation therapy (target international normalised ratio of 2.0-3.0; n=3371) or clopidogrel (75 mg per day) plus aspirin (75-100 mg per day recommended; n=3335). Outcome events were adjudicated by a blinded committee. Primary outcome was first occurrence of stroke, non-CNS systemic embolus, myocardial

2006 Lancet Controlled trial quality: predicted high

399. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. (PubMed)

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Results of trials of aspirin and dipyridamole combined versus aspirin alone for the secondary prevention of vascular events after ischaemic stroke of presumed arterial origin are inconsistent. Our aim was to resolve this uncertainty.We did a randomised controlled trial in which we assigned patients to aspirin (30-325 mg daily) with (n=1363) or without (n=1376 (...) (number ISRCTN73824458) and with (NCT00161070).Mean follow-up was 3.5 years (SD 2.0). Median aspirin dose was 75 mg in both treatment groups (range 30-325); extended-release dipyridamole was used by 83% (n=1131) of patients on the combination regimen. Primary outcome events arose in 173 (13%) patients on aspirin and dipyridamole and in 216 (16%) on aspirin alone (hazard ratio 0.80, 95% CI 0.66-0.98; absolute risk reduction 1.0% per year, 95% CI 0.1-1.8). Addition of the ESPRIT data to the meta

2006 Lancet Controlled trial quality: predicted high

400. Aspirin and the risk of intracranial complications following head injury

Aspirin and the risk of intracranial complications following head injury BestBets: Aspirin and the risk of intracranial complications following head injury Aspirin and the risk of intracranial complications following head injury Report By: Magdy Sakr - Consultant in Emergency Medicine Search checked by Libby Wilson - Clinical Research Fellow Institution: University Hospitals of Coventry and Warwickshire Date Submitted: 12th November 2003 Date Completed: 24th November 2005 Last Modified: 12th (...) November 2003 Status: Green (complete) Three Part Question In [adults with head injury] does [pre-injury aspirin] adversely [affect clinical outcome]? Clinical Scenario A 65 year old man on aspirin presents to the emergency department having fallen sustaining a minor head injury. You wonder whether he is at higher risk of intracranial bleeding due to aspirin. Search Strategy Medline using the OVID interface 1966- August Week 4 2005 Embase 1980–2005 week 37 The Cochrane Library Issue 3 2005 Medline

2005 BestBETS